AAAAAA
Results: 1-25/32
Authors:
den Hartog, FR
van Kalmthout, PM
van Loenhout, TT
Schaafsma, HJ
Rila, H
Verheugt, FWA
Citation: Fr. Den Hartog et al., Pravastatin in acute ischaemic syndromes: Results of a randomised placebo-controlled trial, INT J CL PR, 55(5), 2001, pp. 300-304
Authors:
ten Berg, JM
Kelder, JC
Suttorp, MJ
Verheugt, FWA
Plokker, HWT
Citation: Jm. Ten Berg et al., Influence of planned six-month follow-up angiography on late outcome afterpercutaneous coronary intervention - A randomized study, J AM COL C, 38(4), 2001, pp. 1061-1069
Authors:
Laheij, RJF
Jansen, JBMJ
Verbeek, ALM
Verheugt, FWA
Citation: Rjf. Laheij et al., Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease, ALIM PHARM, 15(7), 2001, pp. 1055-1059
Authors:
Remmen, JJ
Verheugt, FWA
Citation: Jj. Remmen et Fwa. Verheugt, The hotline sessions of the 23rd European Congress of Cardiology, EUR HEART J, 22(22), 2001, pp. 2033-2037
Authors:
Verheugt, FWA
Chesebro, JH
Citation: Fwa. Verheugt et Jh. Chesebro, Acute coronary care and beyond: The expanding role of low-molecular-weightheparin, CLIN CARD, 24(3), 2001, pp. I1-I2
Authors:
Chesebro, JH
Verheugt, FWA
Kontny, F
Fry, ETA
Wallentin, L
Camm, AJ
Bechtold, H
Citation: Jh. Chesebro et al., Evaluating the place of low-molecular-weight heparin in the acute coronarysyndromes, CLIN CARD, 24(3), 2001, pp. I20-I22
Authors:
Verheugt, FWA
Citation: Fwa. Verheugt, GUSTO V: the bottom line of fibrinolytic reperfusion therapy, LANCET, 357(9272), 2001, pp. 1898-1899
Authors:
Verheugt, FWA
Citation: Fwa. Verheugt, GP IIB/IIIA blockers with and without thrombolytic agent in prehospital treatment of acute myocardial infarction, THROMB RES, 103, 2001, pp. S113-S116
Authors:
Verheugt, FWA
Citation: Fwa. Verheugt, Clopidogrel versus aspirin after cardiac surgery, CIRCULATION, 104(13), 2001, pp. E76-E76
Authors:
ten Berg, JM
Hutten, BA
Kelder, JC
Verheugt, FWA
Plokker, HWT
Citation: Jm. Ten Berg et al., Oral anticoagulant therapy during and after coronary angioplasty - The intensity and duration of anticoagulation are essential to reduce thrombotic complications, CIRCULATION, 103(16), 2001, pp. 2042-2047
Authors:
Verheugt, FWA
Citation: Fwa. Verheugt, What about the novel antiplatelet agents?, CHALLENGES IN ACUTE CORONARY SYNDROMES, 2001, pp. 215-222
Authors:
Liem, A
Zijlstra, F
Ottervanger, JP
Hoorntje, JCA
Suryapranata, H
de Boer, MJ
Verheugt, FWA
Citation: A. Liem et al., High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: The Heparin in Early Patency (HEAP) randomized trial, J AM COL C, 35(3), 2000, pp. 600-604
Authors:
Oyen, WJG
Boerman, OC
Brouwers, FM
Barrett, JA
Verheugt, FWA
Ruiter, DJ
Corstens, FHM
van der Meer, J
Citation: Wjg. Oyen et al., Scintigraphic detection of acute experimental endocarditis with the technetium-99m labelled glycoprotein IIb/IIIa receptor antagonist DM P444, EUR J NUCL, 27(4), 2000, pp. 292-299
Authors:
Verheugt, FWA
Citation: Fwa. Verheugt, Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable corollary artery disease, HAEMOSTASIS, 30, 2000, pp. 122-127
Authors:
Bulut, S
Aengevaeren, WRM
Luijten, HJE
Verheugt, FWA
Citation: S. Bulut et al., Successful out-of-hospital cardiopulmonary resuscitation: what is the optimal in-hospital treatment strategy?, RESUSCITAT, 47(2), 2000, pp. 155-161
Authors:
Verheugt, FWA
Citation: Fwa. Verheugt, How hot is inflammation in acute coronary syndrome?, EUR HEART J, 21(24), 2000, pp. 1990-1992
Authors:
Chesebro, JH
Verheugt, FWA
Citation: Jh. Chesebro et Fwa. Verheugt, Introduction: Expanding the horizons in unstable coronary artery disease, CLIN CARD, 23(1), 2000, pp. 1-3
Authors:
Verheugt, FWA
Martin, JF
Ryden, L
Citation: Fwa. Verheugt et al., European cardiology: 50 years, LANCET, 356(9230), 2000, pp. 671-672
Authors:
Lagrand, WK
Visser, CA
Niessen, HWM
Hack, CE
Hermens, WT
Verheugt, FWA
Wolbink, GJ
Hack, CE
Citation: Wk. Lagrand et al., C-reactive protein as a clinical marker of risk - Response, CIRCULATION, 102(9), 2000, pp. E63-E64
Authors:
ten Berg, JM
Kelder, JC
Suttorp, MJ
Mast, EG
Bal, E
Ernst, SMPG
Verheugt, FWA
Plokker, HHT
Citation: Jm. Ten Berg et al., Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up - A randomized trial, CIRCULATION, 102(4), 2000, pp. 386-391
Authors:
Verheugt, FWA
Citation: Fwa. Verheugt, Anticoagulation and certification to fly: risks and benefits of different strategies, EUR H J SUP, 1(D), 1999, pp. D114-D117
Authors:
van den Merkhof, LFM
Zijlstra, F
Olsson, H
Grip, L
Veen, G
Bar, FWHM
van den Brand, MJBM
Simoons, ML
Verheugt, FWA
Citation: Lfm. Van Den Merkhof et al., Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty - Results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study, J AM COL C, 33(6), 1999, pp. 1528-1532
Authors:
Verheugt, FWA
Becker, RC
Bertrand, ME
Bode, C
Chesebro, JH
Cleland, JGF
Conti, R
Hillis, WS
Klein, W
Maseri, A
Turpie, AGG
Wallentin, L
Waters, DD
Citation: Fwa. Verheugt et al., Management strategies in unstable coronary artery disease - Current problems and future directions, CLIN CARD, 22(9), 1999, pp. 551-553
Authors:
Verheugt, FWA
Citation: Fwa. Verheugt, Acute coronary syndromes: interventions, LANCET, 353, 1999, pp. SII16-SII19
Authors:
Verheugt, FWA
Citation: Fwa. Verheugt, Acute coronary syndromes: drug treatments, LANCET, 353, 1999, pp. SII20-SII23